التفاصيل البيبلوغرافية
| العنوان: |
Redetermination of PD-L1 expression after chemioradiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis. |
| المؤلفون: |
Ciammella, Patrizia, Cozzi, Salvatore, Borghetti, Paolo, Galaverni, Marco, Nardone, Valerio, Ruggieri, Maria Paola, Sepulcri, Matteo, Scotti, Vieri, Bruni, Alessio, Zanelli, Francesca, Piro, Roberto, Tagliavini, Elena, Botti, Andrea, Iori, Federico, Alì, Emanuele, Bennati, Chiara, Tiseo, Marcello |
| المصدر: |
Frontiers in Oncology; 2024, p1-7, 7p |
| مصطلحات موضوعية: |
PROGRAMMED death-ligand 1, NON-small-cell lung carcinoma, PEMETREXED |
| مصطلحات جغرافية: |
EUROPE |
| مستخلص: |
Background: Chemoradiation therapy (CRT) is the treatment of choice for locally advanced non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell death 1 (PD1) axis inhibitors with radiotherapy are in development for patients with LA-NSCLC. However, the effect of CRT on tumor cells programmed cell death ligand-1 (PD-L1) expression is unknown. Methods: In this multicentric retrospective study, we analyzed paired NSCLC specimens that had been obtained pre- and post-CRT. PD-L1 expression on tumor cells was studied by immunohistochemistry. The purpose of this study was to evaluate the feasibility, risk of complications, and clinical relevance of performing re-biopsy after CRT in patients with PD-L1 negative LA-NSCLC. Results: Overall, 31 patients from 6 centers with PD-L1 negative LA-NSCLC were analyzed. The percentage of tumor cells with PD-L1 expression significantly increased between pre- and post-CRT specimens in 14 patients (45%). Nine patients had unchanged PD-L1 expression after CRT, in five patients the rebiopsy material was insufficient for PD-L1 analysis and in two patients no tumor cells at rebiopsy were found. The post-rebiopsy complication rate was very low (6%). All patients with positive PD-L1 re-biopsy received Durvalumab maintenance after CRT, except one patient who had a long hospitalization for tuberculosis reactivation. Median PFS of patients with unchanged or increased PD-L1 expression was 10 and 16.9 months, respectively. Conclusion: CRT administration can induce PD-L1 expression in a considerable fraction of PD-L1 negative patients at baseline, allowing them receiving the maintenance Durvalumab in Europe. Hence, after a definitive CRT, PD-L1 redetermination should be considered in patients with LANSCLC PD-L1 negative, to have a better selection of maintenance Durvalumab candidates. [ABSTRACT FROM AUTHOR] |
|
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder